作为肺癌中一个有希望的目标,TROP2:
1Department of Medical Oncology, The First People's Hospital of Linping, Hangzhou, Zhejiang, China.
Frontiers in oncology
|September 12, 2025
概括
热囊细胞表面抗原-2 (TROP2) 是肺癌 (LC) 治疗的一个有希望的目标. 针对TROP2的抗体-药物合物 (ADC) 显示出治疗LC的巨大潜力,为患者管理提供了一个有希望的新途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 肺癌 (LC) 仍然是一个重大的全球健康挑战,需要创新的治疗策略.
- 热囊细胞表面抗原-2 (TROP2) 在包括肺癌在内的各种瘤中表达很高,但在正常组织中表达很小.
- 这种差异表达使得TROP2成为选择性癌症治疗的有吸引力的标.
研究的目的:
- 审查TROP2的特征及其在癌症进展中的参与.
- 为突出TROP2-向抗体-药物合物 (ADCs) 在癌症治疗中的进展.
- 评估TROP2-ADCs在治疗肺癌中的治疗潜力.
主要方法:
- 对TROP2生物学及其在瘤发生中的作用的文献综述.
- 在正常和瘤组织中分析TROP2表达模式.
- 对TROP2向抗体-药物合物 (ADC) 开发和临床数据的评估.
主要成果:
- 在瘤组织,特别是肺癌中,TROP2的过度表达,其表达与疾病进展有关.
- 针对TROP2的ADC在临床前和临床研究中已经证明了其有效性.
- 一种TROP2-ADC已获得FDA批准,验证了其治疗潜力.
结论:
- TROP2是肺癌的验证治疗标.
- TROP2-ADCs代表了LC治疗的重大进展.
- 进一步的研究和TROP2-ADCs的临床应用有望改善肺癌患者的治疗结果.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.6K
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
910
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
